Analyst Research

Report Title Price
Provider: Finlabo SIM Spa
$10.00
Provider: Reuters Investment Profile
$20.00
Provider: Directors Deals Ltd.
$12.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Sorin SpA receives FDA approval for Mitroflow Aortic Heart Valve with New Phospholipid Reduction Treatment


Monday, 28 Apr 2014 07:58am EDT 

Sorin SpA:Receives U.S. Food and Drug Administration (FDA) approval for Mitroflow Aortic Pericardial Heart Valve with PRT.Phospholipid Reduction Treatment (PRT), a patented advanced tissue treatment, is intended to further improve durability of the Mitroflow bioprosthetic valve.Research has demonstrated that phospholipids play key role in calcification process of bioprotheses.PRT has been shown to decrease phospholipid content in pericardial tissue, which led to a reduction of 99 pct of calcium uptake compared to control. 

Company Quote

1.777
0.0070 +0.40%
10:04am EDT